Diabetes, Obesity
Conditions
Brief summary
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in non-diabetic adults with obesity
Interventions
DRUGPF-06882961
PF-68882961 will be provided as tablets twice a day (BID)
OTHERPlacebo
Placebo comparator will be provided as tablets twice daily for 12 weeks
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female participants between the ages of 18 and 75 years, inclusive, at Visit 1 (screening).
Exclusion criteria
* Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes. * History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class II IV heart failure, or transient ischemic attack within 6 months of screening (Visit 1). * Participants with a known medical history of active liver disease (other than non alcoholic hepatic steatosis), including chronic active hepatitis B or C, or primary biliary cirrhosis. * History of major depressive disorder or history of other severe psychiatric disorders (eg, schizophrenia or bipolar disorder) within the last 2 years. * Any lifetime history of a suicide attempt.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Baseline through follow-up (Day 112) | An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (easily tolerated, causing minimal discomfort and not interfering with daily activities), moderate (causing sufficient discomfort and interferes with normal daily activities) and severe (preventing normal daily activities). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Baseline through Visit 10 (Day 91) | Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg. |
| Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Baseline through Visit 10 (Day 91) | ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec. |
| Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0, 2, 4, 6, 8, 10, 12, 13-14 | The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded yes to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes. |
| Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0, 2, 4, 6, 8, 10, 12, 13-14. | The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points. |
| Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | Baseline, Week 2 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Fasting Plasma Glucose at Week 4 | Baseline, Week 4 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Fasting Plasma Glucose at Week 6 | Baseline, Week 6 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Fasting Plasma Glucose at Week 8 | Baseline, Week 8 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Fasting Plasma Glucose at Week 10 | Baseline, Week 10 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Fasting Plasma Glucose at Week 12 | Baseline, Week 12 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | Baseline, Week 2 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Glycolated HbA1c at Week 4 | Baseline, Week 4 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Glycolated HbA1c at Week 6 | Baseline, Week 6 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Glycolated HbA1c at Week 8 | Baseline, Week 8 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | Baseline through Visit 10 (Day 91) | Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. |
| CFB in Glycolated HbA1c at Week 12 | Baseline, Week 12 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
| CFB in Body Weight at Week 2 (Participants With T2DM) | Baseline, Week 2 | Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses. |
| CFB in Body Weight at Week 4 (Participants With T2DM) | Baseline, Week 4 | Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses. |
| CFB in Body Weight at Week 6 (Participants With T2DM) | Baseline, Week 6 | Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses. |
| CFB in Body Weight at Week 8 (Participants With T2DM) | Baseline, Week 8 | Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses. |
| CFB in Body Weight at Week 10 (Participants With T2DM) | Baseline, Week 10 | Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses. |
| CFB in Body Weight at Week 12 (Participants With T2DM) | Baseline, Week 12 | Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses. |
| CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity) | Baseline, Week 2 | Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement. |
| CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity) | Baseline, Week 4 | Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement. |
| CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity) | Baseline, Week 6 | Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement. |
| CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity) | Baseline, Week 8 | Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement. |
| CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity) | Baseline, Week 10 | Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement. |
| CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity) | Baseline, Week 12 | Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement. |
| CFB in Glycolated HbA1c at Week 10 | Baseline, Week 10 | Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. |
Countries
United States
Participant flow
Recruitment details
Participants were enrolled from 06 January 2021 to 17 November 2021 in the United States.
Pre-assignment details
A total of 370 participants were screened for eligibility, of which 151 participants (123 in the type 2 diabetes mellitus \[T2DM\] arms and 28 in the non-diabetic obesity arms) were randomized to receive the danuglipron or placebo in one of the 8 treatment arms.
Participants by arm
| Arm | Count |
|---|---|
| Placebo (T2DM) Participants with T2DM received matching placebo tablets orally twice daily (BID) with food. | 16 |
| Placebo (Non-diabetic Obesity) Participants with non-diabetic obesity received matching placebo tablets orally BID with food. | 6 |
| PF-06882961 80 mg BID Low, Slow (T2DM) Participants with T2DM received PF-06882961 tablets orally BID with food. The dose were titrated from 5 mg to 80 mg over 12 weeks. | 20 |
| PF-06882961 80 mg BID High, Slow (T2DM) Participants with T2DM received PF-06882961 tablets orally BID with food. The dose were titrated from 10 mg to 80 mg over 12 weeks. | 22 |
| PF-06882961 120 mg BID Low, Fast (T2DM) Participants with T2DM received PF-06882961 tablets orally BID with food. The dose were titrated from 5 mg to 120 mg over 12 weeks. | 22 |
| PF-06882961 120 mg BID High, Fast (T2DM) Participants with T2DM received PF-06882961 tablets orally BID with food. The dose were titrated from 10 mg to 120 mg over 12 weeks. | 22 |
| PF-06882961 200 mg BID (T2DM) Participants with T2DM received PF-06882961 tablets orally BID with food. The dose were titrated from 10 mg to 200 mg over 12 weeks. | 21 |
| PF-06882961 200 mg BID (Non-diabetic Obesity) Participants with non-diabetic obesity received PF-06882961 tablets orally BID with food. The dose were titrated from 10 mg to 200 mg over 12 weeks. | 22 |
| Total | 151 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Follow-up Period | Adverse Event | 1 | 1 | 2 | 3 | 4 | 3 | 0 | 3 |
| Follow-up Period | Lost to Follow-up | 0 | 1 | 2 | 0 | 0 | 4 | 0 | 3 |
| Follow-up Period | No longer meets eligibility criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Follow-up Period | Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-up Period | Withdrawal by Subject | 2 | 0 | 0 | 2 | 2 | 0 | 1 | 2 |
| Treatment Period | Adverse Event | 1 | 6 | 4 | 6 | 7 | 8 | 0 | 12 |
| Treatment Period | Lost to Follow-up | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 2 |
| Treatment Period | No longer meets eligibility criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Treatment Period | Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment Period | Withdrawal by Subject | 2 | 0 | 0 | 2 | 2 | 0 | 1 | 2 |
Baseline characteristics
| Characteristic | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous Mean (SD) | 53.9 Years STANDARD_DEVIATION 9.1 | 49.5 Years STANDARD_DEVIATION 5.79 | 59.5 Years STANDARD_DEVIATION 9.55 | 60.9 Years STANDARD_DEVIATION 8.69 | 58.3 Years STANDARD_DEVIATION 7.11 | 57.2 Years STANDARD_DEVIATION 11.8 | 59 Years STANDARD_DEVIATION 9.31 | 48.5 Years STANDARD_DEVIATION 13.12 | 56.5 Years STANDARD_DEVIATION 10.55 |
| Age, Continuous | 53.0 Years | 49.0 Years | 60.5 Years | 61.5 Years | 58.5 Years | 60.0 Years | 59.0 Years | 52.0 Years | 58.0 Years |
| Age, Customized <18 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 18-44 | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 3 Participants | 1 Participants | 7 Participants | 16 Participants |
| Age, Customized 45-64 | 12 Participants | 5 Participants | 12 Participants | 13 Participants | 18 Participants | 12 Participants | 14 Participants | 13 Participants | 99 Participants |
| Age, Customized >=65 | 2 Participants | 0 Participants | 7 Participants | 9 Participants | 3 Participants | 7 Participants | 6 Participants | 2 Participants | 36 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Black or African American | 4 Participants | 0 Participants | 3 Participants | 2 Participants | 2 Participants | 5 Participants | 3 Participants | 4 Participants | 23 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 9 Participants | 3 Participants | 12 Participants | 11 Participants | 9 Participants | 11 Participants | 15 Participants | 13 Participants | 83 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 7 Participants | 3 Participants | 8 Participants | 11 Participants | 13 Participants | 11 Participants | 6 Participants | 9 Participants | 68 Participants |
| Race/Ethnicity, Customized Not reported | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 12 Participants | 6 Participants | 17 Participants | 19 Participants | 19 Participants | 17 Participants | 17 Participants | 18 Participants | 125 Participants |
| Sex: Female, Male Female | 8 Participants | 4 Participants | 10 Participants | 10 Participants | 10 Participants | 10 Participants | 10 Participants | 16 Participants | 78 Participants |
| Sex: Female, Male Male | 8 Participants | 2 Participants | 10 Participants | 12 Participants | 12 Participants | 12 Participants | 11 Participants | 6 Participants | 73 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 16 | 0 / 6 | 0 / 20 | 0 / 22 | 0 / 22 | 0 / 22 | 0 / 21 | 0 / 22 |
| other Total, other adverse events | 8 / 16 | 4 / 6 | 11 / 20 | 13 / 22 | 14 / 22 | 14 / 22 | 14 / 21 | 18 / 22 |
| serious Total, serious adverse events | 0 / 16 | 0 / 6 | 0 / 20 | 0 / 22 | 0 / 22 | 0 / 22 | 0 / 21 | 0 / 22 |
Outcome results
Primary
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (easily tolerated, causing minimal discomfort and not interfering with daily activities), moderate (causing sufficient discomfort and interferes with normal daily activities) and severe (preventing normal daily activities).
Time frame: Baseline through follow-up (Day 112)
Population: Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of investigational products (IP).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 0 Participants |
| Placebo (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 5 Participants |
| Placebo (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 3 Participants |
| Placebo (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 0 Participants |
| Placebo (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 2 Participants |
| Placebo (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 8 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 8 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 10 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 9 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 5 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 7 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 6 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 8 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 7 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 9 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 10 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 3 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Mild | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Moderate | 11 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Severe | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | Treatment Related - Severe | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Mild | 6 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity | All Causality - Moderate | 11 Participants |
Secondary
CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 10
Population: Estimand set 1B that all evaluable non-diabetic participants with obesity randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity) | -0.40 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity) | -3.47 kg |
p-value: 0.05990% CI: [-6.31, 0.17]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 10 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 10
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 10 (Participants With T2DM) | -0.67 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 10 (Participants With T2DM) | -3.14 kg |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Body Weight at Week 10 (Participants With T2DM) | -1.71 kg |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Body Weight at Week 10 (Participants With T2DM) | -4.95 kg |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Body Weight at Week 10 (Participants With T2DM) | -3.35 kg |
| PF-06882961 200 mg BID (T2DM) | CFB in Body Weight at Week 10 (Participants With T2DM) | -4.38 kg |
p-value: 0.011190% CI: [-4.22, -0.7]Mixed Models Analysis
p-value: 0.1690% CI: [-2.75, 0.68]Mixed Models Analysis
p-value: <0.000190% CI: [-6.03, -2.52]Mixed Models Analysis
p-value: 0.006190% CI: [-4.42, -0.94]Mixed Models Analysis
p-value: 0.000590% CI: [-5.52, -1.89]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 12
Population: Estimand set 1B that all evaluable non-diabetic participants with obesity randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity) | -0.11 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity) | -3.85 kg |
p-value: 0.082690% CI: [-8.23, 0.75]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 12 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 12
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 12 (Participants With T2DM) | -0.42 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 12 (Participants With T2DM) | -3.64 kg |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Body Weight at Week 12 (Participants With T2DM) | -1.93 kg |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Body Weight at Week 12 (Participants With T2DM) | -5.38 kg |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Body Weight at Week 12 (Participants With T2DM) | -2.93 kg |
| PF-06882961 200 mg BID (T2DM) | CFB in Body Weight at Week 12 (Participants With T2DM) | -5.37 kg |
p-value: 0.004790% CI: [-5.22, -1.2]Mixed Models Analysis
p-value: 0.100390% CI: [-3.45, 0.44]Mixed Models Analysis
p-value: <0.000190% CI: [-6.96, -2.95]Mixed Models Analysis
p-value: 0.019790% CI: [-4.49, -0.51]Mixed Models Analysis
p-value: <0.000190% CI: [-7.03, -2.85]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 2
Population: Estimand set 1B that all evaluable non-diabetic participants with obesity randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity) | 0.23 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity) | -0.73 kg |
p-value: 0.083690% CI: [-2.12, 0.19]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 2 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 2
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 2 (Participants With T2DM) | -0.14 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 2 (Participants With T2DM) | -0.40 kg |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Body Weight at Week 2 (Participants With T2DM) | -0.22 kg |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Body Weight at Week 2 (Participants With T2DM) | -0.46 kg |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Body Weight at Week 2 (Participants With T2DM) | -0.63 kg |
| PF-06882961 200 mg BID (T2DM) | CFB in Body Weight at Week 2 (Participants With T2DM) | -0.21 kg |
p-value: 0.284390% CI: [-1.02, 0.5]Mixed Models Analysis
p-value: 0.43190% CI: [-0.84, 0.68]Mixed Models Analysis
p-value: 0.240290% CI: [-1.07, 0.43]Mixed Models Analysis
p-value: 0.139790% CI: [-1.24, 0.26]Mixed Models Analysis
p-value: 0.439390% CI: [-0.85, 0.71]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 4
Population: Estimand set 1B that all evaluable non-diabetic participants with obesity randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity) | 0.09 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity) | -1.50 kg |
p-value: 0.038690% CI: [-3.07, -0.12]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 4 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 4
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 4 (Participants With T2DM) | -0.46 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 4 (Participants With T2DM) | -1.23 kg |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Body Weight at Week 4 (Participants With T2DM) | -0.34 kg |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Body Weight at Week 4 (Participants With T2DM) | -1.58 kg |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Body Weight at Week 4 (Participants With T2DM) | -1.47 kg |
| PF-06882961 200 mg BID (T2DM) | CFB in Body Weight at Week 4 (Participants With T2DM) | -0.41 kg |
p-value: 0.149190% CI: [-2, 0.45]Mixed Models Analysis
p-value: 0.566490% CI: [-1.09, 1.34]Mixed Models Analysis
p-value: 0.063290% CI: [-2.33, 0.09]Mixed Models Analysis
p-value: 0.084790% CI: [-2.23, 0.2]Mixed Models Analysis
p-value: 0.526490% CI: [-1.2, 1.3]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 6
Population: Estimand set 1B that all evaluable non-diabetic participants with obesity randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity) | -0.10 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity) | -1.59 kg |
p-value: 0.156690% CI: [-3.99, 1]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 6 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 6
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 6 (Participants With T2DM) | -0.38 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 6 (Participants With T2DM) | -1.86 kg |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Body Weight at Week 6 (Participants With T2DM) | -0.65 kg |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Body Weight at Week 6 (Participants With T2DM) | -2.74 kg |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Body Weight at Week 6 (Participants With T2DM) | -2.23 kg |
| PF-06882961 200 mg BID (T2DM) | CFB in Body Weight at Week 6 (Participants With T2DM) | -1.16 kg |
p-value: 0.013990% CI: [-3.23, -0.47]Mixed Models Analysis
p-value: 0.181590% CI: [-2.19, 0.64]Mixed Models Analysis
p-value: 0.039590% CI: [-2.86, -0.1]Mixed Models Analysis
p-value: 0.372690% CI: [-1.63, 1.1]Mixed Models Analysis
p-value: 0.002890% CI: [-3.74, -0.98]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 8
Population: Estimand set 1B that all evaluable non-diabetic participants with obesity randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity) | 0.26 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity) | -2.36 kg |
p-value: 0.091690% CI: [-5.91, 0.67]Mixed Models Analysis
Secondary
CFB in Body Weight at Week 8 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 8
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Body Weight at Week 8 (Participants With T2DM) | -0.36 kg |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Body Weight at Week 8 (Participants With T2DM) | -2.52 kg |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Body Weight at Week 8 (Participants With T2DM) | -1.08 kg |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Body Weight at Week 8 (Participants With T2DM) | -3.82 kg |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Body Weight at Week 8 (Participants With T2DM) | -2.41 kg |
| PF-06882961 200 mg BID (T2DM) | CFB in Body Weight at Week 8 (Participants With T2DM) | -3.32 kg |
p-value: 0.011290% CI: [-3.71, -0.61]Mixed Models Analysis
p-value: 0.216190% CI: [-2.24, 0.8]Mixed Models Analysis
p-value: 0.000290% CI: [-5.02, -1.92]Mixed Models Analysis
p-value: 0.014790% CI: [-3.59, -0.51]Mixed Models Analysis
p-value: 0.001390% CI: [-4.56, -1.37]Mixed Models Analysis
Secondary
CFB in Fasting Plasma Glucose at Week 10
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 10
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Fasting Plasma Glucose at Week 10 | -23.39 mg/dL |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 10 | -36.24 mg/dL |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 10 | -38.21 mg/dL |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 10 | -57.36 mg/dL |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 10 | -22.08 mg/dL |
| PF-06882961 200 mg BID (T2DM) | CFB in Fasting Plasma Glucose at Week 10 | -37.81 mg/dL |
p-value: 0.167890% CI: [-34.9, 9.21]Mixed Models Analysis
p-value: 0.122390% CI: [-35.85, 6.21]Mixed Models Analysis
p-value: 0.005490% CI: [-55.66, -12.28]Mixed Models Analysis
p-value: 0.539890% CI: [-20.38, 22.99]Mixed Models Analysis
p-value: 0.140990% CI: [-36.56, 7.72]Mixed Models Analysis
Secondary
CFB in Fasting Plasma Glucose at Week 12
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 12
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Fasting Plasma Glucose at Week 12 | -13.09 mg/dL |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 12 | -41.74 mg/dL |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 12 | -40.41 mg/dL |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 12 | -53.94 mg/dL |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 12 | -23.34 mg/dL |
| PF-06882961 200 mg BID (T2DM) | CFB in Fasting Plasma Glucose at Week 12 | -37.48 mg/dL |
p-value: 0.023690% CI: [-52.31, -4.99]Mixed Models Analysis
p-value: 0.022690% CI: [-49.67, -4.97]Mixed Models Analysis
p-value: 0.002290% CI: [-64.11, -17.59]Mixed Models Analysis
p-value: 0.233590% CI: [-33.59, 13.08]Mixed Models Analysis
p-value: 0.049490% CI: [-48.69, -0.08]Mixed Models Analysis
Secondary
CFB in Fasting Plasma Glucose at Week 4
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 4
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Fasting Plasma Glucose at Week 4 | -13.12 mg/dL |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 4 | -16.45 mg/dL |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 4 | -32.77 mg/dL |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 4 | -45.92 mg/dL |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 4 | -48.97 mg/dL |
| PF-06882961 200 mg BID (T2DM) | CFB in Fasting Plasma Glucose at Week 4 | -41.60 mg/dL |
p-value: 0.380490% CI: [-21.41, 14.76]Mixed Models Analysis
p-value: 0.034890% CI: [-37.44, -1.87]Mixed Models Analysis
p-value: 0.001490% CI: [-50.54, -15.05]Mixed Models Analysis
p-value: 0.000790% CI: [-53.9, -17.81]Mixed Models Analysis
p-value: 0.005290% CI: [-46.6, -10.37]Mixed Models Analysis
Secondary
CFB in Fasting Plasma Glucose at Week 6
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 6
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Fasting Plasma Glucose at Week 6 | -3.75 mg/dL |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 6 | -29.33 mg/dL |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 6 | -36.70 mg/dL |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 6 | -43.82 mg/dL |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 6 | -49.22 mg/dL |
| PF-06882961 200 mg BID (T2DM) | CFB in Fasting Plasma Glucose at Week 6 | -37.38 mg/dL |
p-value: 0.02590% CI: [-46.97, -4.18]Mixed Models Analysis
p-value: 0.005390% CI: [-53.95, -11.95]Mixed Models Analysis
p-value: 0.001290% CI: [-61.41, -18.73]Mixed Models Analysis
p-value: 0.000390% CI: [-66.85, -24.1]Mixed Models Analysis
p-value: 0.005590% CI: [-55.19, -12.08]Mixed Models Analysis
Secondary
CFB in Fasting Plasma Glucose at Week 8
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 8
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Fasting Plasma Glucose at Week 8 | -5.90 mg/dL |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 8 | -33.69 mg/dL |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Fasting Plasma Glucose at Week 8 | -31.57 mg/dL |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 8 | -52.84 mg/dL |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Fasting Plasma Glucose at Week 8 | -39.69 mg/dL |
| PF-06882961 200 mg BID (T2DM) | CFB in Fasting Plasma Glucose at Week 8 | -48.02 mg/dL |
p-value: 0.000590% CI: [-62.85, -21.4]Mixed Models Analysis
p-value: 0.012790% CI: [-48.12, -7.47]Mixed Models Analysis
p-value: 0.017190% CI: [-45.51, -5.83]Mixed Models Analysis
p-value: 0.000190% CI: [-67.16, -26.72]Mixed Models Analysis
p-value: 0.003790% CI: [-54.32, -13.27]Mixed Models Analysis
Secondary
CFB in Glycolated HbA1c at Week 10
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 10
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Glycolated HbA1c at Week 10 | -0.32 Percentage |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Glycolated HbA1c at Week 10 | -1.00 Percentage |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Glycolated HbA1c at Week 10 | -1.26 Percentage |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Glycolated HbA1c at Week 10 | -1.48 Percentage |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Glycolated HbA1c at Week 10 | -1.22 Percentage |
| PF-06882961 200 mg BID (T2DM) | CFB in Glycolated HbA1c at Week 10 | -1.36 Percentage |
p-value: 0.011690% CI: [-1.18, -0.19]Mixed Models Analysis
p-value: 0.000890% CI: [-1.43, -0.46]Mixed Models Analysis
p-value: <0.000190% CI: [-1.66, -0.67]Mixed Models Analysis
p-value: 0.001790% CI: [-1.4, -0.4]Mixed Models Analysis
p-value: 0.000490% CI: [-1.55, -0.55]Mixed Models Analysis
Secondary
CFB in Glycolated HbA1c at Week 12
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 12
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Glycolated HbA1c at Week 12 | -0.32 Percentage |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Glycolated HbA1c at Week 12 | -1.07 Percentage |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Glycolated HbA1c at Week 12 | -1.32 Percentage |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Glycolated HbA1c at Week 12 | -1.56 Percentage |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Glycolated HbA1c at Week 12 | -1.04 Percentage |
| PF-06882961 200 mg BID (T2DM) | CFB in Glycolated HbA1c at Week 12 | -1.57 Percentage |
p-value: 0.013290% CI: [-1.32, -0.2]Mixed Models Analysis
p-value: 0.001490% CI: [-1.55, -0.46]Mixed Models Analysis
p-value: 0.000290% CI: [-1.8, -0.69]Mixed Models Analysis
p-value: 0.017490% CI: [-1.29, -0.16]Mixed Models Analysis
p-value: 0.000290% CI: [-1.82, -0.69]Mixed Models Analysis
Secondary
CFB in Glycolated HbA1c at Week 4
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 4
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Glycolated HbA1c at Week 4 | -0.22 Percentage |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Glycolated HbA1c at Week 4 | -0.33 Percentage |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Glycolated HbA1c at Week 4 | -0.59 Percentage |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Glycolated HbA1c at Week 4 | -0.81 Percentage |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Glycolated HbA1c at Week 4 | -0.75 Percentage |
| PF-06882961 200 mg BID (T2DM) | CFB in Glycolated HbA1c at Week 4 | -0.58 Percentage |
p-value: 0.27490% CI: [-0.4, 0.19]Mixed Models Analysis
p-value: 0.019690% CI: [-0.66, -0.08]Mixed Models Analysis
p-value: 0.000690% CI: [-0.88, -0.3]Mixed Models Analysis
p-value: 0.001990% CI: [-0.82, -0.23]Mixed Models Analysis
p-value: 0.024390% CI: [-0.66, -0.06]Mixed Models Analysis
Secondary
CFB in Glycolated HbA1c at Week 6
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 6
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Glycolated HbA1c at Week 6 | -0.26 Percentage |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Glycolated HbA1c at Week 6 | -0.49 Percentage |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Glycolated HbA1c at Week 6 | -0.92 Percentage |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Glycolated HbA1c at Week 6 | -1.11 Percentage |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Glycolated HbA1c at Week 6 | -0.97 Percentage |
| PF-06882961 200 mg BID (T2DM) | CFB in Glycolated HbA1c at Week 6 | -0.93 Percentage |
p-value: 0.158790% CI: [-0.62, 0.15]Mixed Models Analysis
p-value: 0.002790% CI: [-1.04, -0.27]Mixed Models Analysis
p-value: 0.000290% CI: [-1.24, -0.47]Mixed Models Analysis
p-value: 0.001690% CI: [-1.1, -0.32]Mixed Models Analysis
p-value: 0.002790% CI: [-1.07, -0.28]Mixed Models Analysis
Secondary
CFB in Glycolated HbA1c at Week 8
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 8
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Glycolated HbA1c at Week 8 | -0.27 Percentage |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Glycolated HbA1c at Week 8 | -0.71 Percentage |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Glycolated HbA1c at Week 8 | -1.14 Percentage |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Glycolated HbA1c at Week 8 | -1.38 Percentage |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Glycolated HbA1c at Week 8 | -1.20 Percentage |
| PF-06882961 200 mg BID (T2DM) | CFB in Glycolated HbA1c at Week 8 | -1.18 Percentage |
p-value: 0.047290% CI: [-0.86, -0.01]Mixed Models Analysis
p-value: 0.000490% CI: [-1.29, -0.45]Mixed Models Analysis
p-value: <0.000190% CI: [-1.53, -0.68]Mixed Models Analysis
p-value: 0.000390% CI: [-1.36, -0.5]Mixed Models Analysis
p-value: 0.000490% CI: [-1.34, -0.47]Mixed Models Analysis
Secondary
CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 2
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.03 Percentage |
| PF-06882961 80 mg BID Low, Slow (T2DM) | CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.12 Percentage |
| PF-06882961 80 mg BID High, Slow (T2DM) | CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.29 Percentage |
| PF-06882961 120 mg BID Low, Fast (T2DM) | CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.37 Percentage |
| PF-06882961 120 mg BID High, Fast (T2DM) | CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.35 Percentage |
| PF-06882961 200 mg BID (T2DM) | CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.20 Percentage |
p-value: 0.248590% CI: [-0.31, 0.13]Mixed Models Analysis
p-value: 0.025290% CI: [-0.48, -0.04]Mixed Models Analysis
p-value: 0.005390% CI: [-0.56, -0.12]Mixed Models Analysis
p-value: 0.00990% CI: [-0.54, -0.1]Mixed Models Analysis
p-value: 0.106690% CI: [-0.39, 0.05]Mixed Models Analysis
Secondary
Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 2
Population: Estimand Set 1A that all evaluable participants with T2DM randomly assigned to IP and who took at least 1 dose of IP. For participants who discontinued IP and/or received glycemic rescue medication, all subsequent values were censored.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (T2DM) | Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -5.63 mg/dL |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -3.32 mg/dL |
| PF-06882961 80 mg BID High, Slow (T2DM) | Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -23.04 mg/dL |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -36.48 mg/dL |
| PF-06882961 120 mg BID High, Fast (T2DM) | Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -39.29 mg/dL |
| PF-06882961 200 mg BID (T2DM) | Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -25.15 mg/dL |
p-value: 0.586390% CI: [-15.23, 19.85]Mixed Models Analysis
p-value: 0.049490% CI: [-34.75, -0.06]Mixed Models Analysis
p-value: 0.001990% CI: [-48.09, -13.61]Mixed Models Analysis
p-value: 0.000990% CI: [-51, -16.32]Mixed Models Analysis
p-value: 0.034390% CI: [-37.12, -1.92]Mixed Models Analysis
Secondary
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded yes to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes.
Time frame: Week 0, 2, 4, 6, 8, 10, 12, 13-14
Population: Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of IP.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| Placebo (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 6 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 4 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <1> Completed Suicide | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 2 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <2> Suicide Attempt | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <4> Suicidal Ideation | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 8 - <1> Completed Suicide | 0 Participants |
Secondary
Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria
ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec.
Time frame: Baseline through Visit 10 (Day 91)
Population: Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of IP.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 2 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 1 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| Placebo (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >60 msec | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >480 and <=500 msec | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in QRS interval >=50% | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval >=140 msec | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >500 msec | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | %Change in PR interval >=25/50% | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | Change in QTcF interval >30 and <=60 msec | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval >=300 msec | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF interval >450 and <=480 msec | 1 Participants |
Secondary
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.
Time frame: Baseline through Visit 10 (Day 91)
Population: Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of IP.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo (T2DM) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 12 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 4 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 9 Participants |
Secondary
Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points.
Time frame: Week 0, 2, 4, 6, 8, 10, 12, 13-14.
Population: Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of IP.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 10 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 10 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 16 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 16 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 15 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 15 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 4 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 10 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 12 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 11 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 14 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 4 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 5 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 6 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 3 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 6 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 6 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 12 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 6 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 20 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 19 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 20 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 19 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 6 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 20 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 11 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 10 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 8 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 19 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 7 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 11 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 11 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 7 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 11 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 7 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 19 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 3 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 15 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 15 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 8 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 6 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 4 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 19 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 5 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 6 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 5 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 5 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 22 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 21 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 21 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 15 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 19 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 6 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 22 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 22 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 6 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 19 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 15 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 21 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 16 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 17 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 17 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 20 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 16 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 19 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 21 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 15 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 15 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 19 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 19 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 19 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 22 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 22 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 22 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 19 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 20 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 21 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 22 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 5 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 21 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 22 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 20 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 22 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 2 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 19 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 14 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 13 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 19 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 18 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 17 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 20 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 11 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 3 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 17 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 6 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 21 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 21 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 21 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 21 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 17 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 18 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 4 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 3 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 9 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 6 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 9 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 10 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 15 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 11 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 9 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 5 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 6 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 10 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 9 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 4 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 19 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 12 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 18 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 14 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 3 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 18 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 4 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 18 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 17 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 13 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 -Feeling Down Depressed or Hopeless - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Not At All | 10 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Several Days | 3 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Not At All | 17 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Not At All | 10 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Several Days | 4 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Falling or Staying Asleep - Not At All | 10 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Not At All | 17 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Not At All | 10 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Not At All | 18 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Not At All | 18 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 20 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Tired or Little Energy - Not At All | 9 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Not At All | 17 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Trouble Concentrating on Things - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Bad About Yourself - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Not At All | 20 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - Not At All | 9 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Poor Appetite or Overeating - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Tired or Little Energy - Not At All | 9 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Feeling Down Depressed or Hopeless - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Several Days | 7 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Not At All | 9 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Tired or Little Energy - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Concentrating on Things - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Bad About Yourself - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Poor Appetite or Overeating - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Not At All | 21 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Poor Appetite or Overeating - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Tired or Little Energy - Not At All | 10 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Trouble Falling or Staying Asleep - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Feeling Down Depressed or Hopeless - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 8 - Little Interest/Pleasure in Things - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Several Days | 3 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Poor Appetite or Overeating - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Trouble Falling or Staying Asleep - Several Days | 4 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Several Days | 7 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Feeling Down Depressed or Hopeless - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Falling or Staying Asleep - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 17 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Concentrating on Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Nearly Every Day | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Poor Appetite or Overeating - Not At All | 13 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Several Days | 8 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Tired or Little Energy - Not At All | 9 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Trouble Falling or Staying Asleep - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 4 - Little Interest/Pleasure in Things - Not At All | 16 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Thoughts You Be Better Off Dead - Not At All | 20 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Bad About Yourself - Not At All | 19 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Several Days | 3 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Several Days | 5 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Tired or Little Energy - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Down Depressed or Hopeless - Not At All | 19 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Feeling Down Depressed or Hopeless - Not At All | 18 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 2 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Thoughts You Be Better Off Dead - Not At All | 22 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 21 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Several Days | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Trouble Concentrating on Things - Not At All | 20 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Feeling Bad About Yourself - Not At All | 21 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Little Interest/Pleasure in Things - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Thoughts You Be Better Off Dead - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Poor Appetite or Overeating - Not At All | 12 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Trouble Falling or Staying Asleep - Not At All | 9 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 12 - Little Interest/Pleasure in Things - Not At All | 14 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Thoughts You Be Better Off Dead - Not At All | 15 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 0 - Poor Appetite or Overeating - Several Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) | Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 15 Participants |
Secondary
Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg.
Time frame: Baseline through Visit 10 (Day 91)
Population: Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of IP.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 0 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 1 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 0 Participants |
| Placebo (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 2 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 0 Participants |
| PF-06882961 80 mg BID Low, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 2 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 1 Participants |
| PF-06882961 80 mg BID High, Slow (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 2 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 3 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| PF-06882961 120 mg BID Low, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 2 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 4 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| PF-06882961 120 mg BID High, Fast (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 1 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| PF-06882961 200 mg BID (T2DM) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| Placebo (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate >120 bpm | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP <90 mmHg | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Increase >=30 mmHg | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine SBP Decrease >=30 mmHg | 2 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP <50 mmHg | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Increase >=20 mmHg | 0 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine DBP Decrease >=20 mmHg | 1 Participants |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria | Supine Pulse Rate <40 bpm | 0 Participants |